Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8165164 | 0.75 | CYP2C19 (0.41) | CYP2C19 | |
| SCHEMBL8165163 | 0.75 | CYP2C19 (0.41) | CYP2C19 | |
| SCHEMBL243441 | 0.75 | NPSR1 (0.46) | — | |
| SCHEMBL7547696 | 0.72 | NPSR1 (0.47) | — | |
| SCHEMBL3036312 | 0.72 | CYP2C19 (0.37) | CYP2C19 | |
| Acetic Acid SCHEMBL3815500 | 0.70 | ALDH1A1 (0.35) | — | |
| SCHEMBL18109846 | 0.69 | ALDH1A1 (0.35) | — | |
| SCHEMBL8040013 | 0.67 | HPGD (0.40) | — | |
| SCHEMBL5201527 | 0.67 | ALDH1A1 (0.31) | — | |
| SCHEMBL8811482 | 0.67 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785631-B2 | Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core | SEIKAGAKU CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-1611109-A4 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-06-24 | — | — | EP | disclosed |
| US-20090131661-A1 | Oxazolone Derivatives | SEIKAGAKU CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1975162-A1 | OXAZOLONE DERIVATIVE | SEIKAGAKU CORPORATION (JP) | 2008-10-01 | — | — | EP | disclosed |
| CN-1798729-A | Benzamide nitrile derivatives | HOFFMANN LA ROCHE (CH) | 2006-07-05 | — | — | CN | disclosed |
| EP-1611109-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004087680-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131661-A1 | Oxazolone Derivatives | CTSK, CTSZ, CTSV | CYP2C19 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.